Olutasidenib Maintenance

Pilot Trial of Olutasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplantation in Patients Carrying IDH1 Mutation With AML, MDS, or CMML Disease

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
15 patients (estimated)
Sponsors
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Tags
Isocitrate Dehydrogenase 1 (IDH1) Inhibitor, Maintenance, Post-Allogeneic Stem Cell Transplant
Trial Type
Treatment
Last Update
1 week ago
SparkCures ID
1976
NCT Identifier
NCT06543381

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.